EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Host cell proteins in monoclonal antibody processing: Control, detection, and removal

Takao Ito iD, Herb Lutz, Lihan Tan, Bin Wang, Janice Tan, Masum Patel, Lance Chen, Yuki Tsunakawa, Byunghyun Park, Subhasis Banerjee

Biotechnology Progress · 2024-07 · 40 (4)

DOI: 10.1002/btpr.3448 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biotechnology Progress, online erschienen am 13.03.2024. Verfasst von Takao Ito und 9 weiteren Autor:innen. Beteiligte Einrichtung: Life Science, Process Solutions, Merck Ltd. (An Affiliate of Merck KGaA, Darmstadt, Germany), Tokyo, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 151 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Host cell proteins (HCPs) are process‐related impurities in a therapeutic protein expressed using cell culture technology. This review presents biopharmaceutical industry trends in terms of both HCPs in the bioprocessing of monoclonal antibodies (mAbs) and the capabilities for HCP clearance by downstream unit operations. A comprehensive assessment of currently implemented and emerging technologies in the manufacturing processes with extensive references was performed. Meta‐analyses of published downstream data were conducted to identify trends. Improved analytical methods and understanding of “high‐risk” HCPs lead to more robust manufacturing processes and higher‐quality therapeutics. The trend of higher cell density cultures leads to both higher mAb expression and higher HCP levels. However, HCP levels can be significantly reduced with improvements in operations, resulting in similar concentrations of approx. 10 ppm HCPs. There are no differences in the performance of HCP clearance between recent enhanced downstream operations and traditional batch processing. This review includes best practices for developing improved processes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAnimalsHumansCHO CellsProteinsCricetulusCell Culture Techniques

Stichwörter der Autor:innen

cell culturecontinuous bioprocessingdownstream processhost cell proteinmonoclonal antibody

Substanzen

Antibodies, MonoclonalProteins

Autor:innen und Institutionen

  • Life Science, Process Solutions, Merck Ltd. (An Affiliate of Merck KGaA, Darmstadt, Germany), Tokyo, Japan.
  • Independent Consultant, Sudbury, Massachusetts, USA.
  • Life Science Services, Sigma-Aldrich Pte Ltd, Singapore, Singapore.
  • Life Science, Process Solutions, Merck Chemicals (Shanghai) Co. Ltd. (An Affiliate of Merck KGaA Darmstadt, Germany), Shanghai, China.
  • Life Science, Process Solutions, Merck Pte Ltd. (An Affiliate of Merck KGaA, Darmstadt, Germany), Singapore.
  • Life Science, Process Solutions, Merck Life Sciences Pvt. Ltd. (An Affiliate of Merck KGaA, Darmstadt, Germany), Bangalore, India.

ORCID-Profile: Takao Ito

Zitieren

APA

Ito, T., Lutz, H., Tan, L., Wang, B., Tan, J., Patel, M., Chen, L., Tsunakawa, Y., Park, B., & Banerjee, S. (2024). Host cell proteins in monoclonal antibody processing: Control, detection, and removal. Biotechnology Progress, 40(4). https://doi.org/10.1002/btpr.3448

Vancouver

Ito T, Lutz H, Tan L, Wang B, Tan J, Patel M, et al. Host cell proteins in monoclonal antibody processing: Control, detection, and removal. Biotechnology Progress. 2024;40(4). doi:10.1002/btpr.3448

BibTeX
@article{Ito2024,
  author = {Ito, Takao and Lutz, Herb and Tan, Lihan and Wang, Bin and Tan, Janice and Patel, Masum and Chen, Lance and Tsunakawa, Yuki and Park, Byunghyun and Banerjee, Subhasis},
  title = {Host cell proteins in monoclonal antibody processing: Control, detection, and removal},
  journal = {Biotechnology Progress},
  year = {2024},
  volume = {40},
  number = {4},
  doi = {10.1002/btpr.3448}
}
Kostenlos starten →